75 related articles for article (PubMed ID: 21355002)
1. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.
Hwang JH; Lim MC; Seo SS; Park SY; Kang S
Jpn J Clin Oncol; 2011 May; 41(5):624-9. PubMed ID: 21355002
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Rhee CK; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim CH; Shim BY; Kim HK; Sun DS; Kim KH
Lung Cancer; 2011 Apr; 72(1):64-7. PubMed ID: 20832894
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.
Choi CH; Lee YY; Song TJ; Park HS; Kim MK; Kim TJ; Lee JW; Lee JH; Bae DS; Kim BG
Cancer; 2011 May; 117(10):2104-11. PubMed ID: 21523722
[TBL] [Abstract][Full Text] [Related]
4. Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.
Lee GJ; Min JW; Seo MW; Lee MY; Jin JY
J Obstet Gynaecol Res; 2014 Jan; 40(1):297-300. PubMed ID: 24102892
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
Kim SJ; Kim JS; Kim SC; Kim YK; Kim YK; Kang JY; Yoon HK; Song JS; Lee SH; Moon HS; Kim JW; Kim KH; Kim CH; Shim BY; Kim HK
Lung Cancer; 2010 Jun; 68(3):446-9. PubMed ID: 19683359
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.
Look KY; Blessing JA; Levenback C; Kohler M; Chafe W; Roman LD
Gynecol Oncol; 1998 Sep; 70(3):334-8. PubMed ID: 9790784
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
Kim YM; Lee SW; Kim DY; Kim JH; Nam JH; Kim YT
J Chemother; 2010 Jun; 22(3):197-200. PubMed ID: 20566426
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
Lee HP; Seo SS; Ryu SY; Kim JH; Bang YJ; Park SY; Nam JH; Kang SB; Lee KH; Song YS
Gynecol Oncol; 2008 Jun; 109(3):359-63. PubMed ID: 18405948
[TBL] [Abstract][Full Text] [Related]
11. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
Saltz L; Janik JE
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of rubitecan in recurrent or metastatic head and neck cancer.
Caponigro F; Cartenì G; Droz JP; Milano A; Davis WB; Pollard P
Cancer Chemother Pharmacol; 2008 Jul; 62(2):209-14. PubMed ID: 17882418
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix.
Morris M; Brader KR; Burke TW; Levenback CF; Gershenson DM
Gynecol Oncol; 1998 Aug; 70(2):215-8. PubMed ID: 9740693
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Dark GG; Calvert AH; Grimshaw R; Poole C; Swenerton K; Kaye S; Coleman R; Jayson G; Le T; Ellard S; Trudeau M; Vasey P; Hamilton M; Cameron T; Barrett E; Walsh W; McIntosh L; Eisenhauer EA
J Clin Oncol; 2005 Mar; 23(9):1859-66. PubMed ID: 15699482
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Miller DS; Blessing JA; Bodurka DC; Bonebrake AJ; Schorge JO;
Gynecol Oncol; 2008 Jul; 110(1):65-70. PubMed ID: 18455781
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.
Downs LS; Chura JC; Argenta PA; Judson PL; Ghebre R; Geller MA; Carson LF
Gynecol Oncol; 2011 Feb; 120(2):265-9. PubMed ID: 21145100
[TBL] [Abstract][Full Text] [Related]
18. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
Duffaud F; Borner M; Chollet P; Vermorken JB; Bloch J; Degardin M; Rolland F; Dittrich C; Baron B; Lacombe D; Fumoleau P;
Eur J Cancer; 2004 Dec; 40(18):2748-52. PubMed ID: 15571957
[TBL] [Abstract][Full Text] [Related]
20. [Medical treatment of metastatic or recurrent cancer of the cervix].
de la Motte Rouge T; Pautier P; Hamy AS; Duvillard P; Bruna A; Castaigne D; Morice P; Haie-Meder C; Lhommé C
Bull Cancer; 2006 Mar; 93(3):263-70. PubMed ID: 16567313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
